Literature DB >> 24582989

The effect of anesthesia choice on post-operative outcomes in women undergoing exploratory laparotomy for a suspected gynecologic malignancy.

Colleen Rivard1, Elizabeth L Dickson2, Rachel Isaksson Vogel3, Peter A Argenta2, Deanna Teoh2.   

Abstract

OBJECTIVE: To determine how anesthesia choice in women undergoing laparotomy for gynecologic malignancy affects pain control and narcotic use.
METHODS: This is a retrospective study of women who underwent laparotomy for suspected gynecologic malignancy from May 2012 to January 2013. Patients were categorized into one of three groups: 1) patient controlled analgesia (PCA); 2) PCA+transversus abdominis plane block (TAP); and 3) patient-controlled epidural analgesia (PCEA). Mean narcotic use and patient reported pain scores were compared.
RESULTS: The analysis includes 112 women (44 PCA, 30 TAP, 38 PCEA). Intraoperative factors were not different between groups with the exception of a significant difference in the rate of intra-operative complications (p=0.020), with lower rates in the PCEA group. The groups differed in intravenous narcotic use in each of the first three postoperative days (day 0: p=0.014; day 1: p<0.0001; day 2: p=0.048), with patients in the TAP group using the least on day 0 and those in the PCEA group using less on postoperative days 1 and 2. In addition, the PCEA group reported lower pain scores on postoperative days 1 and 2 (day 1: p=0.046; day 2: p=0.008).
CONCLUSIONS: The use of patient controlled epidural anesthesia after laparotomy for gynecologic malignancy is associated with decreased IV and PO narcotic use and improved pain control without increasing complications or length of hospital stay. Further investigation with prospective randomized trials is warranted to elucidate the optimal post-operative pain management technique.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Laparotomy; Pain control; Regional anesthesia; TAP blocks

Mesh:

Substances:

Year:  2014        PMID: 24582989      PMCID: PMC4592284          DOI: 10.1016/j.ygyno.2014.02.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

1.  Bowel function recovery after radical hysterectomies: thoracic epidural bupivacaine-morphine versus intravenous patient-controlled analgesia with morphine: a pilot study.

Authors:  O A de Leon-Casasola; D Karabella; M J Lema
Journal:  J Clin Anesth       Date:  1996-03       Impact factor: 9.452

Review 2.  Surgical stress: the role of pain and analgesia.

Authors:  H Kehlet
Journal:  Br J Anaesth       Date:  1989-08       Impact factor: 9.166

3.  Continuous postoperative epidural analgesia for gynecologic oncology patients.

Authors:  J G Blythe; K A Hodel; T M Wahl; R N Miller; W R Mayfield; S L Schneider
Journal:  Gynecol Oncol       Date:  1990-06       Impact factor: 5.482

4.  Transversus abdominis plane block does not provide additional benefit to multimodal analgesia in gynecological cancer surgery.

Authors:  James D Griffiths; Justine V Middle; Fiona A Barron; Sarah J Grant; Phillip A Popham; Colin F Royse
Journal:  Anesth Analg       Date:  2010-06-14       Impact factor: 5.108

5.  Efficacy of postoperative patient-controlled and continuous infusion epidural analgesia versus intravenous patient-controlled analgesia with opioids: a meta-analysis.

Authors:  Christopher L Wu; Seth R Cohen; Jeffrey M Richman; Andrew J Rowlingson; Genevieve E Courpas; Kristin Cheung; Elaina E Lin; Spencer S Liu
Journal:  Anesthesiology       Date:  2005-11       Impact factor: 7.892

6.  Use of a bupivacaine continuous wound infusion system in gynecologic oncology: a randomized trial.

Authors:  David M Kushner; Regina LaGalbo; Joseph P Connor; Rick Chappell; Sarah L Stewart; Ellen M Hartenbach
Journal:  Obstet Gynecol       Date:  2005-08       Impact factor: 7.661

7.  Postoperative pain management in gynecology oncology patients utilizing epidural opiate analgesia and patient-controlled analgesia.

Authors:  S E Rapp; L B Ready; B E Greer
Journal:  Gynecol Oncol       Date:  1989-12       Impact factor: 5.482

8.  Perioperative outcomes comparing patient controlled epidural versus intravenous analgesia in gynecologic oncology surgery.

Authors:  Lee-May Chen; Vivian K Weinberg; Christine Chen; C Bethan Powell; Lee-Lynn Chen; John K Chan; Daniel H Burkhardt
Journal:  Gynecol Oncol       Date:  2009-09-23       Impact factor: 5.482

9.  A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery.

Authors:  Sarah E Ferguson; Tim Malhotra; Venkatraman E Seshan; Douglas A Levine; Yukio Sonoda; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

10.  The transversus abdominis plane block provides effective postoperative analgesia in patients undergoing total abdominal hysterectomy.

Authors:  John Carney; John G McDonnell; Alan Ochana; Raj Bhinder; John G Laffey
Journal:  Anesth Analg       Date:  2008-12       Impact factor: 5.108

View more
  3 in total

1.  Anaesthetic Drug Choices of Senior Anaesthetists: An Observational Analysis of Medication Habits in a Tertiary Hospital.

Authors:  Laura Münst; Martin Schläpfer; Peter Biro
Journal:  Turk J Anaesthesiol Reanim       Date:  2018-09-04

2.  Guidelines for postoperative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations--Part II.

Authors:  G Nelson; A D Altman; A Nick; L A Meyer; P T Ramirez; C Achtari; J Antrobus; J Huang; M Scott; L Wijk; N Acheson; O Ljungqvist; S C Dowdy
Journal:  Gynecol Oncol       Date:  2016-01-03       Impact factor: 5.482

3.  Improved Postoperative Pain Control for Cytoreductive Surgery in Women With Ovarian Cancer Using Patient-Controlled Epidural Analgesia.

Authors:  Tak Kyu Oh; Myong Cheol Lim; Yumi Lee; Jung Yeon Yun; Seungmin Yeon; Sang-Yoon Park
Journal:  Int J Gynecol Cancer       Date:  2016-03       Impact factor: 3.437

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.